Pfizer Balances Cost Cuts and Portfolio Growth as US Pricing Rules Take Shape

Pfizer's stock climbs 18% year-to-date as new HHS documents reveal a most-favored-nation deal with redacted pricing terms.

Pfizer finds itself navigating two distinct storylines that rarely appear in the same headline: a steady climb in its share price and a widening web of contractual obligations to the US government. Freshly released documents from the Department of Health and Human Services (HHS) have pulled back the curtain — partially, at least — on how the company's pricing commitments will actually work.

According to Bloomberg, a most-favored-nation agreement requires Pfizer to hand over a portion of any additional revenue it earns if the deal prompts it to raise drug prices abroad. The exact percentage and the specific medicines covered were blacked out in the paperwork, which surfaced through a Freedom of Information Act lawsuit. As media reports on September 22 noted, those heavy redactions left key questions unanswered, including how the arrangement dovetails with other US pricing initiatives and what tangible economic upside participating drugmakers stand to gain.

The disclosure landed just days after the White House confirmed on September 18 that Medicaid programs in all 50 states would join the so-called GENEROUS most-favored-nation model. Pfizer is among the manufacturers that have signed on.

International Revenue at Stake

The stakes are hardly trivial. More than 40 percent of Pfizer's revenue comes from outside the United States, meaning any mechanism that ties overseas pricing to domestic rebates could ripple through the top line. In exchange for surrendering a slice of higher foreign net revenues, the company secures exemptions from certain US tariffs, tied to investments in domestic manufacturing capacity.

Management has been candid about the regulatory landscape. At the Morgan Stanley Global Healthcare Conference on September 14, CEO Albert Bourla addressed political risks, looming patent expirations, and competition from Chinese biotech firms — while also spotlighting the company's newer medicines.

New Products Carry the Load

Those newer treatments, along with assets acquired through deals, are generating roughly $13 billion on an annualized basis, growing at a pace of about 20 percent. The figure underscores Pfizer's effort to offset revenue lost to expiring patents.

The second quarter offered concrete evidence of that strategy at work. New and acquired products — including portfolios from the Seagen and Biohaven acquisitions — contributed $3.2 billion in revenue. Padcev, the cancer drug, was a standout, with quarterly sales climbing to $667 million. Oncology's momentum is cushioning the drag from fading vaccine revenue and patent losses.

Cost discipline is the other half of the equation. Pfizer is targeting annual savings of about $6.7 billion by 2029 through cost adjustments, supplemented by further efficiency gains in manufacturing. The savings program was expanded again this year.

Guidance Rises Despite COVID Reset

Those operational improvements gave management room to lift the midpoint of its full-year revenue forecast by $500 million to $61.5 billion, even as it trimmed expectations for COVID-related products. The broader drug portfolio is doing the heavy lifting.

Investors have taken notice. The stock closed at EUR 25.15 last Friday and is up 18 percent year-to-date, trading within striking distance of its 52-week high of EUR 25.34 — just about 1.0 percent below that peak at a recent price of EUR 25.09. The recovery marks a turnaround from earlier cycles, when the shares absorbed steep valuation discounts.

Legal Fronts and Shareholder Returns

Beyond the portfolio, Pfizer is chasing unpaid bills from earlier supply contracts. The Wall Street Journal reported that a Belgian court ruling prompted air traffic safety organization Eurocontrol to freeze transfers of route charges to Poland and ring-fence Romanian funds. At issue: EUR 1.9 billion in outstanding payments for vaccine deliveries.

On the governance side, a mandatory SEC filing showed Bourla acquired 22 phantom stock units on September 16 through the company's deferred compensation plan, payable in cash after leaving service.

For income-focused investors, the quarterly dividend holds steady at $0.43 per share — a fixed point of return as generic and biosimilar competition looms over older blockbusters in the coming quarters. Whether the new most-favored-nation models meaningfully reshape Pfizer's international pricing will depend on how those contractual terms are put into practice.